Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria: Funding Will Be Provided by SAIC through Its Malaria Vaccine Production and Support Services Contract with the National Institute of Allergy and Infectious Diseases (NIAID)

Abstract:
Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria. Funding for the initiative will be provided by SAIC through its Malaria Vaccine Production and Support Services contract with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health. Selecta's subcontract is part of a collaborative effort by NIAID and the US Agency for International Development (USAID) to jointly develop novel therapeutics and vaccines for malaria and will be funded under SAIC's contract (number N01.AI.05421) with NIAID.

Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria: Funding Will Be Provided by SAIC through Its Malaria Vaccine Production and Support Services Contract with the National Institute of Allergy and Infectious Diseases (NIAID)

Watertown, MA | Posted on August 31st, 2011

"We are extremely pleased that we have been selected to apply our novel vaccine platform to the development of a vaccine for malaria," said Werner Cautreels, Ph.D., President and CEO of Selecta Biosciences. "This collaboration accelerates our progress to apply Selecta's advanced vaccine technology to address the significant unmet medical needs in malaria and highlights the breadth of our vaccine technology to treat a range of diseases that impact human health, including infectious diseases, autoimmune diseases, and smoking cessation."

Under the terms of the award, the targeted Synthetic Vaccine Particle (tSVP™) vaccine for malaria will be developed by Selecta for testing in preclinical studies by SAIC collaborators. tSVP™ products are fully-integrated synthetic nanoparticle vaccines engineered to mimic the properties of natural pathogens to elicit a maximal immune response. Selecta's tSVP™ vaccines are ideally suited to induce a strong immune response to antigens, which has proven to be challenging with other vaccine approaches for certain infectious diseases, such as malaria. Selecta designs tSVP™ products to deliver antigen and adjuvant combinations within the same biodegradable nanoparticle, thus ensuring a focused and durable response while keeping off-target effects at a low level.

####

About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta’s SVP™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVP™) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVP™).

Targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples for applications include cancer, infectious diseases and addiction. Targeted tolerogenic Synthetic Vaccine Particles (t2SVP™) are designed to induce antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies and transplant rejection.

Selecta’s pipeline currently contains a vaccine for smoking cessation and relapse prevention, a vaccine for Type 1 Diabetes, vaccines for several infectious diseases (universal influenza, universal human papillomavirus, and malaria), and research approaches with cancer vaccines and in the field of allergies.

Building on the company’s novel approach, Selecta’s product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases. Selecta Biosciences is based in Watertown, Massachusetts, USA.

For more information, please click here

Contacts:
The Yates Network
Kathryn Morris
845-635-9828

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Govt.-Legislation/Regulation/Funding/Policy

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

NIST offers electronics industry 2 ways to snoop on self-organizing molecules October 22nd, 2014

Nanomedicine

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Announcements

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

New-Contracts/Sales/Customers

Dyesol Signs Letter of Intent with Tata Steel October 13th, 2014

HZO Teams With Deutsche Telekom to Unveil the Waterproof Tolino Vision 2 eReader: The New HZO Protected eReader Ushers in a New Era of Waterproof Electronics, Providing a Seamless User Experience Without the Risk of Using Port Doors and Mechanical Seals October 10th, 2014

Fullerex: Talga Resources Joins INSCX™ Exchange September 4th, 2014

Global Energy Systems Signs Master Sales Agreement with China Aviation Supplies Group September 4th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE